Qiagen (QGEN) is back on investors’ radar after recent share price swings, with the stock showing a small 1 day gain and mixed returns over the past year and past 3 months. See our latest analysis for ...

Qiagen is moving into syndromic testing for bloodstream infections with the launch of the Netherlands-based diagnostics maker ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 ...

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...

Qiagen (NYSE:QGEN) said it completed the acquisition of DNA-biometrics company Verogen for $150M. Verogen develops DNA-based biometric human identification products for analysis of forensic genomic ...

Fintel reports that on April 14, 2026, Barclays downgraded their outlook for Qiagen N.V. (NYSE:QGEN) from Overweight to Equal ...

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow ...

Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide ...

Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Wednesday, 2026-02-04. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will report ...